Better Health for All

Caris Life Sciences' core business, molecular profiling for cancer treatment, aims to improve patient outcomes and personalize therapies, with 100% of its offerings focused on health benefits. The company states that most insurance plans cover its molecular testing and offers financial assistance programs for patients, but specific pricing details or the percentage of patients reached by these programs are not provided.

However, Caris Molecular Intelligence (CMI) guided treatment costs £995 per cycle per patient, which is significantly lower than NGS-only treatment at £2,795 per cycle per patient. The Medical College of Wisconsin Cancer Center, a partner in Caris' Precision Oncology Alliance, serves a region with large, underserved populations experiencing cancer disparities, and is committed to reducing the cancer burden for all patients through research. Caris demonstrates a revolutionary commitment to health innovation, having generated over 13 quadrillion data points and performed over 6.5 million tests, and invests in advanced molecular profiling technologies. Caris also shows exceptional data responsibility by developing a scalable, data-aware, and secure infrastructure to manage massive amounts of molecular profiling data. The company's participation in clinical trials is noted, but specific ethical conduct or diversity metrics are not provided, only that the MCWCC conducts over 200 cancer clinical trials.

Honest & Fair Business

Caris Life Sciences encourages employees to report compliance concerns through various channels, including email, phone, and online, and states that investigations are conducted according to written policies.

However, there is no evidence of independent investigation processes. The company's CAPA & Complaints Analyst leads complaint investigations from intake through closure, ensuring accurate classification, documentation, and root cause analysis within required timelines, with a median resolution time of approximately 90 days. Caris maintains a comprehensive Compliance Program that meets standards outlined in the AdvaMed Code of Ethics and the OIG Compliance Guidance for Clinical Laboratories, but the frequency and effectiveness metrics of its training are not specified.

No War, No Weapons

Caris Life Sciences' core business is precision medicine for cancer treatment, which is a civilian application.

The company's CODEai platform and other AI applications are focused on molecular diagnostics and cancer research. There is no evidence in the provided articles that Caris Life Sciences derives revenue from arms or defense contracts, develops or sells dual-use technologies with military applications, or that its AI systems are used militarily or have potential military uses. The company's operations do not involve weapons, military technology, or conflict-related activities, thus rendering several KPIs as not applicable.

Planet-Friendly Business

Caris Life Sciences has not disclosed specific targets for emissions reduction or any formal climate pledges, nor does it participate in tracked reduction initiatives.

The company has also not declared a net-zero target year. However, no regulatory actions, violations, fines, or compliance issues are mentioned in the provided articles. The company's Scope 3 emissions intensity decreased from 0.00049 kg CO2e per € gross profit in 2022 to 0.00037 kg CO2e per € gross profit in 2023. Detailed Scope 1 and Scope 2 emissions data are not available.

Safe & Smart Tech

Caris Life Sciences provides strong user data control, allowing patients to request restrictions, confidential communications, access, amendments, and an accounting of disclosures of their medical information.

Users also have rights to know, delete, correct, opt out of sale, sharing, targeted advertising, and profiling, with an appeal process for denied requests. The company states it collects only necessary data for providing services and takes data minimization steps like pseudonymization or anonymization before sharing data for research. Caris declares compliance with HIPAA, California Health and Safety Code, AdvaMed Code of Ethics, OIG Compliance Guidance for Clinical Laboratories, EU GDPR, UK GDPR, CCPA, and the Swiss Federal Act on Data Protection. However, the company acknowledges that no security measures can be 100% secure and that it is subject to cybersecurity risks. Critical vulnerabilities are patched within 21-30 days on average. Security testing coverage is limited, with 40-55% of systems undergoing regular security testing, and a comprehensive methodology only for critical systems.